90 related articles for article (PubMed ID: 20530446)
1. Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study.
Stathopoulos GP; Rigatos SK; Stathopoulos J
Anticancer Res; 2010 Apr; 30(4):1317-21. PubMed ID: 20530446
[TBL] [Abstract][Full Text] [Related]
2. Liposomal cisplatin: a new cisplatin formulation.
Stathopoulos GP
Anticancer Drugs; 2010 Sep; 21(8):732-6. PubMed ID: 20671511
[TBL] [Abstract][Full Text] [Related]
3. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
4. Maximum tolerated dose and early response - results of a phase I trial of paclitaxel and cisplatin with radiation therapy in carcinoma of the cervix.
Prasad E; Viswanathan PN; Rangad VF; Pavamani S; Ram TS
Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):488-93. PubMed ID: 19386478
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
McMeekin DS; Walker JL; Hartenbach EM; Bookman MA; Koh WJ;
Gynecol Oncol; 2009 Jan; 112(1):134-41. PubMed ID: 18962846
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
7. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
Shapiro GI; Tibes R; Gordon MS; Wong BY; Eder JP; Borad MJ; Mendelson DS; Vogelzang NJ; Bastos BR; Weiss GJ; Fernandez C; Sutherland W; Sato H; Pierceall WE; Weaver D; Slough S; Wasserman E; Kufe DW; Von Hoff D; Kawabe T; Sharma S
Clin Cancer Res; 2011 May; 17(10):3431-42. PubMed ID: 21220472
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
[TBL] [Abstract][Full Text] [Related]
11. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of S-1 administration and a 24-h infusion of cisplatin plus paclitaxel in patients with advanced gastric cancer.
Iwase H; Shimada M; Tsuzuki T; Okeya M; Kobayashi K; Hibino Y; Watanabe H; Goto H
Anticancer Res; 2006; 26(2B):1605-9. PubMed ID: 16619579
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer.
Farhat FS; Temraz S; Kattan J; Ibrahim K; Bitar N; Haddad N; Jalloul R; Hatoum HA; Nsouli G; Shamseddine AI
Clin Breast Cancer; 2011 Dec; 11(6):384-9. PubMed ID: 21993011
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer.
Nakamura T; Fuwa N; Takayama K; Inokuchi H; Tomoda T; Takada A; Makita C; Shiomi M; Yokouchi J; Watanabe K
Head Neck; 2012 Nov; 34(11):1634-9. PubMed ID: 22179897
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02).
Takahashi T; Saikawa Y; Fukuda K; Funakoshi S; Kawakubo H; Takeuchi H; Takaishi H; Kitagawa Y
Anticancer Res; 2012 Dec; 32(12):5401-6. PubMed ID: 23225443
[TBL] [Abstract][Full Text] [Related]
18. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.
Boulikas T
Expert Opin Investig Drugs; 2009 Aug; 18(8):1197-218. PubMed ID: 19604121
[TBL] [Abstract][Full Text] [Related]
19. Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events.
Murata S; Onozawa S; Kim C; Tajima H; Kimata R; Uchida E; Kumita S
Acta Radiol; 2014 Sep; 55(7):793-801. PubMed ID: 24097815
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601).
Nakayama N; Koizumi W; Sasaki T; Higuchi K; Tanabe S; Nishimura K; Katada C; Nakatani K; Takagi S; Saigenji K
Oncology; 2008; 75(1-2):1-7. PubMed ID: 18719348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
